QUIZ: The ALEX Study for ALK+ Non-Small Cell Lung Cancer
In our lung cancer quiz, you’ll get to test your knowledge on the ALEX study.
What characteristics of alectinib therapy made it a viable treatment option versus crizotinib.
a. It has greater potency/selectivity for ALK.
b. It is a central nervous system penetrant.
c. It has the ability to target resistance mutations.
d. All of the above
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Quiz: Best Second-Line Tx for Metastatic Lung SCC and Crohn Disease?
March 1st 2018Are there special second-line considerations for an SCC lung patient with a history of Crohn disease who progressed on first-line carboplatin and gemcitabine? Can any pretreatment tests be deferred for a patient with a history of heavy smoking and a single solitary nodule found on his CT chest scan? Take this multiquestion quiz to find out.
Quiz: Are EGFR Mutations and ALK Rearrangements in Lung Cancer Mutually Exclusive?
February 1st 2018Know when to change targeted therapies in patients with progressive lung cancer? How about appropriate patient criteria for segmentectomy or wedge resection? Test your knowledge in our latest quiz.
Quiz: How Common Are ROS1 Rearrangements in Patients With Lung Cancer?
January 1st 2018In patients with stage IIIA non–small-cell lung cancer, should the presence of N2 disease be determined by both radiologic and invasive staging prior to treatment initiation? Are ALK rearrangements and EGFR mutations mutually exclusive? Test your knowledge in our latest quiz.
